Study of Daily Pentoxifylline as a Rescue Treatment in Duchenne Muscular Dystrophy

Inclusion Criteria: * Male * Age 7 years to 100 years * Ability to ambulate for 10 meters. Assistive devices are allowed. * Diagnosis of DMD confirmed by at least one the following: * On stable dose of prednisone, prednisolone or deflazacort for at least 12 months prior to screening. * Participants who are on stable dose of any combination of the following compounds (creatine, glutamine, coenzyme Q10, vitamin E, C or D, JUVEN, arginine, calcium) must have taken these medications for at least 2 months prior to screening. Subjects are not required to take these medications to participate in the study. * All other herbs, supplements or green tea (other than those noted above) have been discontinued 3 months prior to screening. * Ability to provide reproducible QMT bicep score with no more than 15% variation between scores during screening. * Normal blood clotting ability evidenced by a platelet function assessment (PFA). Exclusion Criteria: * Currently enrolled in another treatment clinical trial. * History of significant concomitant illness or significant impairment of renal or hepatic function. * History of impairment of blood clotting ability (as evidenced by increased PT/PTT or PFA over the upper limit of normal (ULN)). * Recent cerebral or retinal hemorrhage. * History of bleeding diathesis or gastric ulcer.